Abstract
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with metastatic non-small cell lung cancers (NSCLC) harbouring epidermal growth factor receptor mutations (EGFRm). However, the role of TKIs is not established in the management of stage III EGFRm disease. We describe the real-world practice of EGFRm testing and use of TKIs in stage III NSCLC in the KINDLE study, a multicentre, multi-country observational non-interventional study.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
